APBB2 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited, polyclonal knockout population of human HT29 colorectal adenocarcinoma cells, carrying targeted disruption of the APBB2 gene. This heterogeneous pool comprises multiple independent gene-disruption events, providing a robust loss-of-function model while retaining the genetic diversity inherent to polyclonal editing. The cells are supplied as a living culture suitable for immediate use in functional studies.
The HT29 parental cell line was established from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female. HT29 cells are widely used in cancer research due to their ability to form polarized epithelial monolayers and express markers of intestinal differentiation. This line serves as a well-characterized model for colorectal cancer biology, drug response, and intestinal epithelial physiology.
APBB2 encodes an adaptor protein that bridges the APP intracellular domain (AICD) with the histone acetyltransferase Tip60, forming a transcriptional regulatory complex. Nuclear AICD?CAPBB2?CTip60 controls expression of downstream genes such as KAI1 (CD82), GSK3??, BACE1, and p53. APBB2 also integrates Reelin signaling by binding Dab1 and modulates actin cytoskeleton dynamics via interaction with Mena (ENAH). Upstream signals including amyloid beta, AICD, and Reelin converge on APBB2 to regulate cell adhesion, migration, and apoptosis.
In the context of HT29 colorectal adenocarcinoma, loss of APBB2 function is highly relevant for investigating mechanisms of cancer cell migration and invasion. APBB2 links APP/AICD signaling to metastatic behavior, and this knockout model enables researchers to dissect how AICD-dependent transcription contributes to colon cancer progression. Additionally, the cells offer a platform to examine the role of APBB2 in maintaining epithelial polarity and apoptosis resistance.
The polyclonal knockout population is suitable for a range of experimental applications, including transwell migration and invasion assays, co-immunoprecipitation to detect APBB2?CTip60?CDab1 complexes, luciferase reporter assays, and immunofluorescence microscopy. Apoptosis can be assessed via Annexin V staining, and cell viability can be monitored in drug sensitivity studies. For further information, please contact Ascent Research.
